Normoftal vs NNZ-2591
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Eye Peptide Bioregulator, Retina Peptide
Normoftal is an obscure Russian eye supplement from the Khavinson 'peptide bioregulator' tradition, sold as short peptides meant to support the retina. Be clear-eyed about this one: it is marketed as a dietary supplement, not an approved drug, and the evidence behind it is thin and comes almost entirely from one research lineage. We keep the claims minimal on purpose.
Also: Cyclo-L-glycyl-L-2-allylproline, Cyclic glycine-proline analog
NNZ-2591 is Neuren Pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cGP), a small ring-shaped molecule the body makes when it breaks down IGF-1. It is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: Phelan-McDermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and Angelman and Pitt Hopkins syndromes behind it. Phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Normoftal | NNZ-2591 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Khavinson's bioregulator theory holds that very short peptides (two to four amino acids) extracted from or modeled on a specific tissue can act as tissue-specific signals, switching gene expression and protein synthesis back toward normal in that organ. Normoftal is the eye/retina version, described as containing a synthesized peptide (marketed as 'AKS-G,' reportedly lysine and glutamic acid) intended to support retinal cells. The proposed mechanism is that the peptide corrects an age- or disease-related 'peptide deficiency' and restores normal cellular function in the retina. This is a hypothesis from one school of research, not a mechanism confirmed by independent molecular studies, and the specific composition claims come from vendors rather than peer-reviewed identification. | Cyclic glycine-proline is thought to fine-tune IGF-1 activity in the brain by changing how IGF-1 binds to its carrier protein IGFBP-3. A 2014 Scientific Reports study proposed that cGP nudges IGF-1 activity up when it is low and down when it is high, a normalizing effect rather than a simple boost. NNZ-2591 adds an allyl group to the proline ring, making it resistant to enzymes and able to reach the brain after oral dosing. Trial protocols also describe reduced neuroinflammation and support for synapse function in animal models. It is a close cousin of trofinetide in spirit (both are small IGF-1-derived molecules from the same company), but the exact way it helps in these genetic syndromes has not been pinned down in humans. |
| Common Dosing | 2 capsules 1-2x daily 1-2x daily, before meals | 12 mg/kg twice daily (phase 2 target trial dose) Twice daily |
| Administration | Oral capsules, before meals | Oral liquid |
| Typical Duration | 30-day courses, repeat after 2-6 months | 13 weeks in phase 2 and phase 3 trials, with 12-month open-label extensions |
| Best Time to Take | Morning and evening, before meals | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Normoftal is sold in Russia as a dietary supplement and is marketed for retinal degeneration, glaucoma, cataracts, diabetic retinopathy, and post-surgical recovery. Here is the part that matters most: it is not FDA-approved, and the evidence for Khavinson-style retinal bioregulators is heavily concentrated within Khavinson's own institute and clinical program, not replicated by independent international groups to modern standards. The related pharmaceutical Retinalamin is registered for clinical use in Russia, but that registration reflects the Russian system, not FDA or EMA review. There are essentially no rigorous, independent, placebo-controlled trials specific to Normoftal itself in mainstream literature. Treat the marketed eye-health benefits as unproven claims, and treat confidence in this compound as low. | The human data so far come from three small, open-label phase 2 trials of 13 weeks each, all with twice-daily oral dosing titrated up to a target of 12 mg/kg. In Phelan-McDermid syndrome (18 children, published in Neurology Genetics in 2026), 10 of 14 efficacy measures improved significantly from baseline, including clinician and caregiver global ratings, behavior, sleep and communication, and the drug was well tolerated with mostly mild to moderate side effects. Angelman syndrome (reported August 2024) showed a mean CGI-I of 3.0, with 11 of 13 children rated improved by clinicians. Pitt Hopkins syndrome (reported May 2024) showed improvement in 6 of 11 children on clinician-rated severity. The big caveat: none of these had a placebo group, and rare-disease trials with caregiver-rated outcomes are especially prone to placebo effects. A planned Prader-Willi trial was withdrawn before enrolling anyone. The real test is Koala, a randomized, double-blind, placebo-controlled phase 3 trial in about 160 children aged 3 to 12 with Phelan-McDermid syndrome (first patient dosed February 2026; estimated primary completion late 2027), with an open-label extension started in 2026. The FDA has given the program Fast Track, Rare Pediatric Disease and Orphan Drug designations. Neuren has also started work in neonatal hypoxic-ischemic encephalopathy, which is still preclinical. |
Frequently Asked Questions: Normoftal vs NNZ-2591
What is the difference between Normoftal and NNZ-2591?
Normoftal is a cognitive peptide that normoftal is an obscure russian eye supplement from the khavinson 'peptide bioregulator' tradition, sold as short peptides meant to support the retina. be clear-eyed about this one: it is marketed as a dietary supplement, not an approved drug, and the evidence behind it is thin and comes almost entirely from one research lineage. we keep the claims minimal on purpose. NNZ-2591 is a cognitive peptide that nnz-2591 is neuren pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cgp), a small ring-shaped molecule the body makes when it breaks down igf-1. it is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: phelan-mcdermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and angelman and pitt hopkins syndromes behind it. phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Normoftal or NNZ-2591?
Neither is universally "better" - the choice depends on your specific goals. Normoftal is typically used for cognitive purposes, while NNZ-2591 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Normoftal and NNZ-2591 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Normoftal and NNZ-2591 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.